
ORAGENICS INC — Investor Relations & Filings
Oragenics, Inc. is a development-stage biotechnology company focused on developing therapeutics for neurological disorders. The company utilizes a proprietary intranasal delivery technology for targeted, non-invasive administration of pharmaceutical medications to the brain. Its lead candidate, ONP-002, is being developed as a potential treatment for concussion. The company's platform technology is also being explored for applications in other neurodegenerative diseases and central nervous system (CNS) disorders, with the goal of transforming patient care in neurology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEFA14A | 2026-05-20 | English | |
| DEF 14A | 2026-05-20 | English | |
| 8-K | 2026-05-19 | English | |
| 10-Q - ORAGENICS INC (0001174940) (Filer) | 2026-05-08 | English | |
| 8-K - ORAGENICS INC (0001174940) (Filer) | 2026-05-07 | English | |
| 8-K - ORAGENICS INC (0001174940) (Filer) | 2026-04-13 | English |
Browse filings by year
21 years- 2026 13 filings
- 2025 54 filings
- 2024 82 filings
- 2023 55 filings
- 2022 52 filings
- 2021 56 filings
- 2020 63 filings
- 2019 42 filings
- 2018 62 filings
- 2017 40 filings
- 2016 40 filings
- 2015 27 filings
- 2014 46 filings
- 2013 67 filings
- 2012 55 filings
- 2011 51 filings
- 2010 63 filings
- 2009 39 filings
- 2008 60 filings
- 2007 30 filings
- 2006 9 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46691576 | DEFA14A | 2026-05-20 | English | ||
| 46691220 | DEF 14A | 2026-05-20 | English | ||
| 46537661 | 8-K | 2026-05-19 | English | ||
| 44397978 | 10-Q - ORAGENICS INC (0001174940) (Filer) | 2026-05-08 | English | ||
| 42920867 | 8-K - ORAGENICS INC (0001174940) (Filer) | 2026-05-07 | English | ||
| 34413047 | 8-K - ORAGENICS INC (0001174940) (Filer) | 2026-04-13 | English | ||
| 33012236 | EFFECT - ORAGENICS INC (0001174940) (Filer) | 2026-03-23 | English | ||
| 32989861 | S-3/A - ORAGENICS INC (0001174940) (Filer) | 2026-03-19 | English | ||
| 28364041 | S-3 Filing | 2026-01-22 | English | ||
| 28364037 | 8-K Filing | 2026-01-22 | English | ||
| 28364031 | 4/A Filing | 2026-01-22 | English | ||
| 28364039 | SCHEDULE 13G Filing | 2026-01-21 | English | ||
| 28364044 | 8-K Filing | 2026-01-20 | English | ||
|
2025
2 filings
| |||||
| 11534068 | PRIMARY DOCUMENT | 2025-12-15 | English | ||
| 11534070 | PRIMARY DOCUMENT | 2025-12-15 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AIM ImmunoTech Inc.
Immuno-pharma company developing therapeutics for oncology,…
|
AIM | US | Professional, scientific and te… |
|
Ainos, Inc.
Develops AI-driven diagnostics, immune therapeutics, and te…
|
AIMD | US | Professional, scientific and te… |
|
Akela Pharma Inc.
Integrated drug developer focused on pain and inhalation, p…
|
— | CA | Professional, scientific and te… |
|
Akero Therapeutics, Inc.
Clinical-stage company developing treatments for serious me…
|
AKRO | US | Professional, scientific and te… |
|
Aladdin Healthcare Technologies SE
Develops AI-powered tools for drug discovery and diagnostic…
|
NMI | DE | Professional, scientific and te… |
|
Alamar Biosciences, Inc.
Powering precision proteomics for earliest disease detectio…
|
ALMR | US | Professional, scientific and te… |
|
Alaunos Therapeutics, Inc.
Clinical-stage immuno-oncology company developing TCR-T cel…
|
TCRT | US | Professional, scientific and te… |
|
ALGORAE PHARMACEUTICALS LIMITED
Biopharmaceutical firm using AI to develop neurodegenerativ…
|
1AI | AU | Professional, scientific and te… |
|
Aligos Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing thera…
|
ALGS | US | Professional, scientific and te… |
|
Allelix Biopharmaceuticals Inc.
Biopharmaceutical R&D focused on protein-based drugs and ne…
|
ALX | CA | Professional, scientific and te… |
ORAGENICS INC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35380/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35380 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35380 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35380 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35380}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ORAGENICS INC (id: 35380)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.